Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms

Pathophysiology

Volumn 18, Issue 1, 2011, Pages 3-12

  Alexander, J Steven ^a   Zivadinov, Robert ^b   Maghzi, Amir Hadi ^c,d   Ganta, Vijay C ^a   Harris, Meghan K ^e   Minagar, Alireza ^e  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e Louisiana State University Health Sciences Center   (United States)

Author keywords

Blood brain barrier; Endothelial cell; MRI; Multiple sclerosis

Indexed keywords

BETA INTERFERON; CD31 ANTIGEN; CD51 ANTIGEN; CLAUDIN; CXCL13 CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GADOLINIUM; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ALLERGIC ENCEPHALOMYELITIS; ANGIOGENESIS; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CONTRAST ENHANCEMENT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; HUMAN; IMMUNOREGULATION; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 78650540697     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2010.04.002     Document Type: Review

References (73)

1. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
2. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
3. Geurts J.J., Stys P.K., Minagar A., Amor S., Zivadinov R. Gray matter pathology in (chronic) MS: modern views on an early observation. J. Neurol. Sci. 2009, 282:12-20.
4. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul. Pharmacol. 2002, 38:323-337.
5. Ando-Akatsuka Y., Saitou M., Hirase T., Kishi M., Sakakibara A., Itoh M., Yonemura S., Furuse M., Tsukita S. Interspecies diversity of the occludin sequence: cDNA cloning of human, mouse, dog, and rat-kangaroo homologues. J. Cell. Biol. 1996, 133:43-47.
6. Furuse M., Hirase T., Itoh M., Nagafuchi A., Yonemura S., Tsukita S., Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. J. Cell. Biol. 1993, 123:1777-1788.
7. Piontek J., Winkler L., Wolburg H., Müller S.L., Zuleger N., Piehl C., Wiesner B., Krause G., Blasig I.E. Formation of tight junction: determinants of homophilic interaction between classic claudins. FASEB J. 2008, 22:146-158.
8. Wolburg H., Wolburg-Buchholz K., Kraus J., Rascher-Eggstein G., Liebner S., Hamm S., Duffner F., Grote E.H., Risau W., Engelhardt B. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol. 2003, 105:586-592.
9. Nitta T., Hata M., Gotoh S., Seo Y., Sasaki H., Hashimoto N., Furuse M., Tsukita S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell. Biol. 2003, 161:653-660.
10. Liebner S., Kniesel U., Kalbacher H., Wolburg H. Correlation of tight junction morphology with the expression of tight junction proteins in blood-brain barrier endothelial cells. Eur. J. Cell. Biol. 2000, 79:707-717.
11. Morita K., Sasaki H., Furuse M., Tsukita S. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J. Cell. Biol. 1999, 147:185-194.
12. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler. Thromb. Vasc. Biol. 2008, 28:223-232.
13. Kirk J., Plumb J., Mirakhur M., McQuaid S. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J. Pathol. 2003, 201:319-327.
14. Plumb J., McQuaid S., Mirakhur M., Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain. Pathol. 2002, 12:154-169.
15. Minagar A., Ostanin D., Long A.C., Jennings M., Kelley R.E., Sasaki M., Alexander J.S. Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult. Scler. 2003, 9:235-238.
16. Friese M.A., Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann. Neurol. 2009, 66:132-141.
17. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
18. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
19. Love S. Demyelinating diseases. J. Clin. Pathol. 2006, 59:1151-1159.
20. Minagar A., Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 2003, 9:540-549.
21. Bamforth S.D., Kniesel U., Wolburg H., Engelhardt B., Risau W. A dominant mutant of occludin disrupts tight junction structure and function. J. Cell. Sci. 1999, 112:1879-1888.
22. Minagar A., Long A., Ma T., Jackson T.H., Kelley R.E., Ostanin D.V., Sasaki M., Warren A.C., Jawahar A., Cappell B., Alexander J.S. Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium 2003, 10:299-307.
23. Minagar A., Jy W., Jimenez J.J., Sheremata W.A., Mauro L.M., Mao W.W., Horstman L.L., Ahn Y.S. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001, 56:1319-1324.
24. Sheremata W.A., Jy W., Delgado S., Minagar A., McLarty J., Ahn Y. Interferon-beta1a reduces plasma CD31+ endothelial microparticles (CD31+ EMP) in multiple sclerosis. J. Neuroinflammation 2006, 3:23.
25. Jy W., Minagar A., Jimenez J.J., Sheremata W.A., Mauro L.M., Horstman L.L., Bidot C., Ahn Y.S. Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis. Front. Biosci. 2004, 9:3137-3144.
26. Jimenez J., Jy W., Mauro L.M., Horstman L.L., Ahn E.R., Ahn Y.S., Minagar A. Elevated endothelial microparticle-monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-beta 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Mult. Scler. 2005, 11:310-315.
27. Hickey W.F., Hsu B.L., Kimura H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 1991, 28:254-260.
28. Olson T.S., Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Int. Comp. Physiol. 2002, 283:R7-R28.
29. del Zoppo G.J., Milner R. Integrin-matrix interactions in the cerebral microvasculature. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1966-1975.
30. Allavena R., Noy S., Andrews M., Pullen N. CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am. J. Pathol. 2010, 176:556-562.
31. Doring A., Wild M., Vestweber D., Deutsch U., Engelhardt B. E- and P-selectin are not required for the development of experimental autoimmune encephalomyelitis in C57BL/6 and SJL mice. J. Immunol. 2007, 179:8470-8479.
32. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J. Neural. Transm. 2006, 113:477-485.
33. Engelhardt B. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J. Neurol. Sci. 2008, 274:23-26.
34. Bahbouhi B., Berthelot B.L., Pettré S., Michel L., Wiertlewski S., Weksler B., Romero I.A., Miller F., Couraud P.O., Brouard S., Laplaud D.A., Soulillou J.P. Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line. J. Leukoc. Biol. 2009, 86:1049-1063.
35. Battistini L., Piccio L., Rossi B., Bach S., Galgani S., Gasperini C., Ottoboni L., Ciabini D., Caramia M.D., Bernardi G., Laudanna C., Scarpini E., McEver R.P., Butcher E.C., Borsellino G., Constantin G. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003, 101:4775-4782.
36. Kerfoot S., Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J. Immunol. 2002, 169:1000-1006.
37. Deshpande P., King I.L., Segal B.M. IL-12 driven upregulation of P-selectin ligand on myelin-specific T cells is a critical step in an animal model of autoimmune demyelination. J. Neuroimmunol. 2006, 173:35-44.
38. Rebenko-Moll N.M., Liu L., Cardona A., Ransohoff R.M. Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details. Curr. Opin. Immunol. 2006, 18:683-689.
39. Alt C., Laschinger M., Engelhardt B. Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2002, 32:2133-2144.
40. Krumbholz M., Theil D., Cepok S., Hemmer B., Kivisäkk P., Ransohoff R.M., Hofbauer M., Farina C., Derfuss T., Hartle C., Newcombe J., Hohlfeld R., Meinl E. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006, 129:200-211.
41. Sellebjerg F., Börnsen L., Khademi M., Krakauer M., Olsson T., Frederiksen J.L., Sørensen P.S. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73:2003-2010.
42. Cepok S., Schreiber H., Hoffmann S., Zhou D., Neuhaus O., von Geldern G., Hochgesand S., Nessler S., Rothhammer V., Lang M., Hartung H.P., Hemmer B. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch. Neurol. 2009, 66:1216-1223.
43. Omari K.M., Lutz S.E., Santambrogio L., Lira S.A., Raine C.S. Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1. Am. J. Pathol. 2009, 174:164-176.
44. Proia P., Schiera G., Salemi G., Ragonese P., Savettieri G., Di Liegro I. Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis. Int. J. Mol. Med. 2009, 24:743-747.
45. Cunnea P., McMahon J., O'Connell E., Mashayekhi K., Fitzgerald U., McQuaid S. Gene expression analysis of the microvascular compartment in multiple sclerosis using laser microdissected blood vessels. Acta Neuropathol. 2009.
46. Alexander J.S., Minagar A., Harper M., Robinson-Jackson S., Jennings M., Smith S.J. Proteomic analysis of human cerebral endothelial cells activated by multiple sclerosis serum and IFNbeta-1b. J. Mol. Neurosci. 2007, 32:169-178.
47. Bates D.O., Harper S.J. Regulation of vascular permeability by vascular endothelial growth factors. Vascul. Pharmacol. 2002, 39:225-237.
48. Isner J.M., et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996, 348:370-374.
49. Jain R.K. Molecular regulation of vesselmaturation. Nat. Med. 2003, 9:685-693.
50. Hiehle J.F., et al. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn. Reson. Med. 1994, 32:285-293.
51. Proescholdt M.A., Heiss J.D., Walbridge S., Mühlhauser J., Capogrossi M.C., Oldfield E.H., Merrill M.J. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J. Neuropathol. Exp. Neurol. 1999, 58:613-627.
52. Proescholdt M.A., Jacobson S., Tresser N., Oldfield E.H., Merrill M.J. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J. Neuropathol. Exp. Neurol. 2002, 61:914-925.
53. Kappos L., Moeri D., Radue E.W., Schoetzau A., Schweikert K., Barkhof F., et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999, 353:964-969.
54. Sormani M.P., Bonzano L., Roccatagliata L., Cutter G.R., Mancardi G.L., Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann. Neurol. 2009, 65:268-275.
55. Zivadinov R., Leist T.P. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J. Neuroimaging 2005, 15:10S-21S.
56. Cotton F., Weiner H.L., Jolesz F.A., Guttmann C.R. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003, 60:640-646.
57. Guttmann C.R., Ahn S.S., Hsu L., Kikinis R., Jolesz F.A. The evolution of multiple sclerosis lesions on serial MR. Am. J. Neuroradiol. 1995, 16:1481-1491.
58. Rovira A., Alonso J., Cucurella G., Nos C., Tintore M., Pedraza S., et al. Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. Am. J. Neuroradiol. 1999, 20:1939-1945.
59. van Waesberghe J.H., van Walderveen M.A., Castelijns J.A., Scheltens P., Lycklama A., Nijeholt G.J., Polman C.H., et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. Am. J. Neuroradiol. 1998, 19:675-683.
60. Zivadinov R. Evidence for neuroprotection in multiple sclerosis: can imaging techniques measure neuroprotection and remyelination?. Neurology 2007, 68:S72-S82.
61. Cadavid D., Wolansky L.J., Skurnick J., Lincoln J., Cheriyan J., Szczepanowski K., et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009, 72:1976-1983.
62. Barkhof F., Bruck W., De Groot C.J., Bergers E., Hulshof S., Geurts J., et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch. Neurol. 2003, 60:1073-1081.
63. Patrikios P., Stadelmann C., Kutzelnigg A., Rauschka H., Schmidbauer M., Laursen H., et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129:3165-3172.
64. Bagnato F., Jeffries N., Richert N.D., Stone R.D., Ohayon J.M., McFarland H.F., et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003, 126:1782-1789.
65. Bagnato F., Gupta S., Richert N.D., Stone R.D., Ohayon J.M., Frank J.A., et al. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch. Neurol. 2005, 62:1684-1688.
66. Dalton C.M., Miszkiel K.A., Barker G.J., MacManus D.G., Pepple T.I., Panzara M., et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J. Neurol. 2004, 251:407-413.
67. Filippi M., Rovaris M., Rocca M.A., Sormani M.P., Wolinsky J.S., Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes" Neurology 2001, 57:731-733.
68. Dousset V., Brochet B., Deloire M.S., Lagoarde L., Barroso B., Caille J.M., et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. Am. J. Neuroradiol. 2006, 27:1000-1005.
69. Vellinga M.M., Oude Engberink R.D., Seewann A., Pouwels P.J., Wattjes M.P., van der Pol S.M., et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 2008, 131:800-807.
70. Vellinga M.M., Vrenken H., Hulst H.E., Polman C.H., Uitdehaag B.M., Pouwels P.J., et al. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. J. Magn. Reson. Imaging 2009, 29:774-779.
71. DiPerri C., Dwyer M., Wack D., Cox J.L., Hashmi K., Saluste E., et al. Lesion characteristics at 1.5 and 3Tesla in multiple sclerosis patients and healthy controls: a morphological and topological quantitative comparison study. Mult. Scler. 2008, 14:S102.
72. Erskine M.K., Cook L.L., Riddle K.E., Mitchell J.R., Karlik S.J. Resolution-dependent estimates of multiple sclerosis lesion loads. Can. J. Neurol. Sci. 2005, 32:205-212.
73. Sicotte N.L., Voskuhl R.R., Bouvier S., Klutch R., Cohen M.S., Mazziotta J.C. Comparison of multiple sclerosis lesions at 1.5 and 3.0Tesla. Invest. Radiol. 2003, 38:423-427.